Topics

Cancer
FDA approves new ovarian cancer drug
FDA approves new ovarian cancer drug

Opening a new chapter in the use of genomic science to fight cancer, the Food & Drug Administration on Friday approved olaparib, a medication for advanced ovarian cancer associated with a defective BRCA gene. The new drug, to be marketed under the commercial name Lynparza, was found in a preliminary clinical trial to shrink or eliminate ovarian tumors in women whose cancers bore a specific genetic fingerprint and who had undergone at least three prior lines of chemotherapy. Based on Lynparza's "existing objective response rate and duration of response data," the drug safety agency granted the medication's maker, Astra-Zeneca, an "accelerated" approval....

Loading